Plain-English translation of NCT04044534 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our PTSD research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial examined whether could help treat post-traumatic stress disorder (PTSD). Researchers studied how this medication might reduce PTSD symptoms and calm overactivity in a part of the brain involved in fear and stress responses. The trial aimed to better understand whether this new approach could offer relief for people living with PTSD.
Current treatments for PTSD don't work equally well for everyone, and researchers are looking for new options. This trial explored whether this medication might work differently than existing treatments to reduce trauma-related symptoms and help the brain's stress response return to normal.
Participants in this trial received either the nasal insulin spray (40 units twice daily) or a placebo spray, and researchers monitored how well the medication worked on their PTSD symptoms. The study also involved brain imaging scans to examine changes in how the brain was responding to stress. Participants likely attended visits over several weeks so researchers could track their symptoms and safety.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States
Testing effectiveness
Sponsor
VA Connecticut Healthcare System
Enrollment target
~10 participants
Started
October 2024
Primary completion
May 2026
Age range
21 Years – 65 Years
Last updated on clinicaltrials.gov in July 2026.